List of Excipients in Branded Drug VICOPROFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	HYPROMELLOSES
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	MAGNESIUM STEARATE
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	POLYETHYLENE GLYCOL
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	POLYSORBATE 80
Physicians Total Care Inc	VICOPROFEN	hydrocodone bitartrate and ibuprofen	54868-4035	PROPYLENE GLYCOL

Vicoprofen Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Vicoprofen is an immediate-release fixed-dose tablet containing hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg. Its commercial opportunity is no longer based on brand exclusivity. The value lies in differentiated generic or 505(b)(2) products that improve manufacturability, tablet robustness, dissolution control, supply security, or opioid-risk management without changing the approved clinical profile.

The original Vicoprofen formulation used conventional tablet excipients, including microcrystalline cellulose, croscarmellose sodium, povidone, starch, colloidal silicon dioxide, sodium lauryl sulfate, and stearic acid. These materials create a relatively accessible formulation platform for generic development, but any change affecting drug release, bioavailability, stability, or abuse-deterrence claims can increase FDA requirements.

What is Vicoprofen and what excipients does it contain?

Vicoprofen combines an opioid analgesic with a nonsteroidal anti-inflammatory drug:

Attribute	Vicoprofen
Active ingredients	Hydrocodone bitartrate and ibuprofen
Strength	Hydrocodone bitartrate equivalent to 7.5 mg hydrocodone, plus ibuprofen 200 mg
Dosage form	Immediate-release oral tablet
Original sponsor	Knoll Pharmaceutical Company, later associated with Abbott
FDA approval	1997, NDA 20-716
Indication	Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Controlled substance	Schedule II hydrocodone combination product
Primary formulation issue	Balancing rapid hydrocodone release with ibuprofen dissolution, stability, and dose uniformity

The Vicoprofen label identifies conventional excipients used for tablet structure and processing. These include microcrystalline cellulose as a diluent, croscarmellose sodium as a disintegrant, povidone as a binder, starch, colloidal silicon dioxide as a glidant, sodium lauryl sulfate as a wetting agent, and stearic acid as a lubricant.[1]

The formulation is technically straightforward compared with extended-release opioid systems. Its principal development challenge is achieving equivalent dissolution for two active ingredients with different physicochemical properties while maintaining tablet hardness and low friability.

What excipient functions are most important in Vicoprofen tablets?

Disintegration and dissolution

Croscarmellose sodium and starch support rapid tablet breakup. A generic developer must control disintegration without creating excessive hydrophobicity from the lubricant system. Over-lubrication with stearic acid can slow wetting and dissolution, particularly if blending time is not tightly controlled.

Sodium lauryl sulfate can improve wetting of hydrocodone and ibuprofen, but its concentration requires control. Excess surfactant may affect tablet performance, gastrointestinal tolerability, or dissolution behavior.

A practical formulation strategy is to use:

• Microcrystalline cellulose or silicified microcrystalline cellulose for compactability.
• Croscarmellose sodium or crospovidone for rapid disintegration.
• Low-level colloidal silicon dioxide to improve flow.
• Povidone or pregelatinized starch to support granule strength.
• A controlled lubricant addition step to avoid dissolution delays.

Content uniformity

Hydrocodone is present at a low mass relative to ibuprofen and the excipient matrix. Content uniformity therefore presents a greater risk for hydrocodone than for ibuprofen. Ordered mixing, geometric dilution, low-shear blending, and validated segregation controls are commercially important.

A high-value excipient opportunity is a co-processed diluent with improved content-uniformity performance for low-dose, high-potency actives. Such a platform could reduce blend segregation and shorten process development for generic manufacturers.

Tablet strength and packaging

Vicoprofen tablets must withstand high-volume bottling, transportation, and dispensing while disintegrating rapidly after administration. Direct compression is attractive because it reduces process steps and avoids water or heat exposure. However, the formulation must maintain flow and compaction despite the different particle sizes and densities of hydrocodone salt, ibuprofen, and excipients.

Moisture-control excipients and high-barrier packaging can protect against:

• Ibuprofen degradation.
• Tablet softening or hardening.
• Hydrocodone assay drift.
• Discoloration.
• Dissolution changes during shelf life.

A formulation using low-moisture excipients, desiccant packaging, or an aluminum-aluminum blister could support premium positioning where supply-chain stability is important.

What formulation opportunities exist for Vicoprofen generics?

Direct-compression Vicoprofen tablets

The lowest-risk opportunity is an immediate-release tablet that matches the reference product's strength, release profile, and route of administration. This approach is generally suitable for an ANDA if the product meets bioequivalence and pharmaceutical-equivalence requirements.

Commercial differentiation can come from:

• Lower tablet weight.
• Improved hardness and friability.
• Fewer manufacturing steps.
• Reduced dependence on a single excipient supplier.
• Better stability under temperature and humidity stress.
• Smaller, easier-to-swallow tablets.

The formulation should avoid unnecessary excipient changes that create additional dissolution or bioequivalence risk.

Fast-disintegrating or orally disintegrating formats

An orally disintegrating tablet could improve administration for patients who have difficulty swallowing. The opportunity is constrained by hydrocodone's controlled-substance status and by the bitter taste of opioid actives.

Taste masking may require polymer coating, ion-exchange technology, or complexation. Those technologies can delay release or create dose-uniformity issues. A product with a materially different dosage form would likely be better suited to a 505(b)(2) pathway than a conventional ANDA, depending on the final composition and labeling claims.

Abuse-deterrent formulations

An abuse-deterrent hydrocodone/ibuprofen product could use a hard-to-crush matrix, gelling polymer, aversive excipient, or physical barrier. FDA's abuse-deterrent guidance distinguishes laboratory manipulation resistance from evidence of reduced abuse in actual use.[2]

The commercial case is limited by the combination product's ibuprofen content. Patients who manipulate the tablet to extract hydrocodone would also encounter ibuprofen, and the nonopioid component can create additional toxicity risk. A formulation designed to deter tampering must therefore preserve ibuprofen release and safety while meeting opioid abuse-deterrence requirements.

This is a technically differentiated but higher-cost opportunity. It would likely require new clinical or human-abuse-potential evidence, new labeling work, and a 505(b)(2) strategy rather than a simple generic substitution.

Gastrointestinal-risk-oriented formulations

Ibuprofen is associated with gastrointestinal bleeding, ulceration, renal toxicity, and cardiovascular risk. Enteric coating or delayed ibuprofen release could theoretically reduce gastric exposure, but it would change the pharmacokinetic and therapeutic profile of the combination.

A gastroprotective product could combine hydrocodone/ibuprofen with a proton-pump inhibitor or other protective agent. That would be a new combination product, not a simple Vicoprofen generic, and would require substantial clinical justification. The strongest commercial opportunity is therefore not a broad safety claim but a carefully defined product for a population with a documented need for combined analgesia and acid suppression.

When does Vicoprofen lose exclusivity and what is the Orange Book status?

Vicoprofen's original market protection has expired. The product was approved in 1997, and generic hydrocodone/ibuprofen tablets entered the U.S. market after the expiration of the original regulatory and patent barriers.

Protection category	Vicoprofen position
New chemical entity exclusivity	Expired
Original approval date	1997
Original patent estate	Historical protection; no meaningful remaining exclusivity for a conventional Vicoprofen generic
Orange Book strategy	ANDA applicants can generally pursue an immediate-release generic pathway
Current commercial barrier	Controlled-substance regulation, bioequivalence, manufacturing controls, and market economics

Orange Book-listed patents, if any historical listings remain associated with the reference product, do not create a practical barrier comparable to active protection for a new molecular entity. A current applicant must still review the applicable Orange Book record and patent certifications before filing. Paragraph IV certification becomes relevant only if an unexpired, listed patent claims the reference product, its formulation, or an approved method of use.[3]

How do Paragraph IV challenges affect Vicoprofen generic entry?

Paragraph IV risk is lower than for a product with active formulation or method-of-use patents. For Vicoprofen, the principal pathway is likely a paragraph III certification where a listed patent remains but has not expired, or a paragraph IV certification if the applicant contests validity, enforceability, or infringement.

The main litigation risks would involve:

• Formulation claims covering the hydrocodone/ibuprofen combination.
• Manufacturing claims directed to tablet preparation.
• Method-of-use claims covering acute pain treatment.
• Patent listings that do not accurately describe the proposed generic product.
• 30-month-stay litigation after a paragraph IV notice.

Because the active ingredients are old and the reference product is immediate release, a new entrant's highest legal exposure is more likely to come from a later formulation patent than from the original product patent estate. Excipient substitution can reduce infringement risk when claims are composition-specific, but it does not eliminate risk where claims are written broadly around the active-ingredient combination or dissolution profile.

What FDA regulatory pathway applies to a Vicoprofen reformulation?

ANDA pathway

An ANDA is the preferred pathway for a conventional generic tablet that is pharmaceutically equivalent to the reference listed drug. The applicant must demonstrate, among other requirements:

• Same active ingredients.
• Same dosage form and route of administration.
• Equivalent strength.
• Comparable labeling, subject to permitted generic changes.
• Bioequivalence.
• Adequate chemistry, manufacturing, and controls data.

Excipients may differ from those in the reference product if the finished product remains acceptable and bioequivalent. Differences in colorants, flavors, or inactive ingredients may require specific FDA justification.

505(b)(2) pathway

A 505(b)(2) application is more suitable for:

• Abuse-deterrent technology.
• Orally disintegrating or buccal formats.
• Delayed or modified release.
• New combination products.
• Gastroprotective co-formulations.
• New dosing regimens or clinically differentiated delivery systems.

The 505(b)(2) route can support product differentiation, but it carries greater development cost and clinical risk than a standard ANDA.

What patent opportunities exist for Vicoprofen excipients and formulations?

Excipient patents are commercially relevant even when they are not listed in the Orange Book. Potentially protectable subject matter includes:

Patent target	Commercial purpose
Co-processed diluent-disintegrant	Better compactability and faster disintegration
Low-segregation blend	Improved hydrocodone content uniformity
Moisture-resistant tablet	Longer shelf life and lower packaging cost
Abuse-deterrent matrix	Reduced crushability or extraction
Taste-masked dosage form	Improved swallowing and adherence
Controlled-release architecture	Differentiated exposure profile
Manufacturing process	Lower granulation time, lower reject rate, improved scale-up
Packaging system	Protection from humidity and temperature excursions

The strongest patent strategy would claim measurable formulation performance rather than merely naming familiar excipients. Useful claim parameters could include dissolution windows, crushing force, extraction yield, friability, moisture uptake, or stability after defined stress conditions.

A developer should separate three patent layers:

1. Product patents covering the tablet composition.
2. Process patents covering manufacture.
3. Use or labeling patents covering a differentiated clinical population.

Only some patents may qualify for Orange Book listing. Process patents and many excipient-use patents generally do not provide the same regulatory leverage as a listed product patent.

How strong is the commercial opportunity for Vicoprofen excipients?

The opportunity is moderate for enabling technologies and weak for an undifferentiated conventional tablet.

Attractive opportunities

• Excipient systems that improve direct compression.
• Low-segregation blends for low-dose opioids.
• Moisture-resistant formulations.
• Supply-secure alternatives to commonly used excipients.
• Abuse-deterrent platforms that preserve immediate release.
• Contract development and manufacturing services for controlled-substance tablets.

Less attractive opportunities

• A standard tablet with no cost or quality advantage.
• Premium pricing based only on minor excipient substitutions.
• Complex modified-release technology without a clear clinical benefit.
• A new combination product without reimbursement support.
• Formulation claims that cannot be distinguished analytically from existing generics.

Generic hydrocodone/ibuprofen is subject to price competition, restricted opioid prescribing, state-level limits, and pharmacy purchasing controls. Publicly available information does not establish a large standalone revenue base for the discontinued Vicoprofen brand. Revenue exposure is therefore concentrated in generic volume, contract manufacturing, and excipient platform sales rather than brand conversion.

What generic launch scenarios exist for Vicoprofen?

Scenario	Product concept	Regulatory route	Commercial assessment
Base case	7.5/200 mg immediate-release tablet	ANDA	Lowest development risk, highest price pressure
Manufacturing-led	Smaller, harder, more stable tablet	ANDA if equivalent	Moderate opportunity through cost and quality
Patient-convenience	Orally disintegrating or smaller tablet	Likely 505(b)(2)	Differentiated but higher regulatory cost
Risk-management	Abuse-deterrent tablet	505(b)(2) or specialized pathway	Potential institutional value, substantial evidence burden
GI-focused	Delayed ibuprofen or co-formulated gastroprotection	505(b)(2)	Clinically differentiated, high development risk
Supply-chain platform	Co-processed excipient system licensed to generic firms	Product-specific filings by licensees	Scalable B2B opportunity

What manufacturing and geographic barriers affect Vicoprofen?

The active pharmaceutical ingredients are available from multiple qualified suppliers, but hydrocodone manufacturing and distribution are controlled by U.S. Schedule II requirements. Manufacturers need DEA registration, quota management, controlled-substance security, inventory reconciliation, and auditable distribution systems.[4]

Geographic expansion also requires separate regulatory strategies:

• United States: ANDA or 505(b)(2), DEA controls, state opioid requirements.
• European Union: hydrocodone regulatory status varies and commercial precedent is limited.
• Canada: opioid and NSAID requirements differ from the United States.
• Emerging markets: registration may be possible, but hydrocodone access and procurement can be restricted.

The most defensible international strategy is often a platform based on ibuprofen-containing opioid combinations or nonopioid analgesic delivery rather than direct Vicoprofen commercialization.

Key Takeaways

• Vicoprofen contains hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg in an immediate-release tablet.
• Its original excipient system is conventional and does not create a high barrier to generic replication.
• The best excipient opportunities involve direct compression, low segregation, moisture control, tablet robustness, and supply security.
• A conventional generic should generally use the ANDA pathway.
• Abuse-deterrent, orally disintegrating, modified-release, or gastroprotective products would likely require a 505(b)(2) strategy.
• Original Vicoprofen exclusivity has expired, and current commercial barriers are regulatory and operational rather than molecule-level patent barriers.
• Controlled-substance compliance and opioid market contraction reduce the value of an undifferentiated product.
• The most scalable business model is an excipient or manufacturing platform licensed to multiple generic or specialty pharmaceutical companies.

FAQs About Vicoprofen Excipient Strategy

Can a generic Vicoprofen use different excipients?

Yes. FDA permits inactive-ingredient differences when the proposed product meets applicable pharmaceutical equivalence, bioequivalence, safety, quality, and labeling requirements.

Is Vicoprofen an extended-release product?

No. Vicoprofen is an immediate-release tablet. A delayed-release or extended-release version would be a materially different product.

Are Vicoprofen excipient patents listed in the Orange Book?

Excipient and manufacturing patents are not automatically Orange Book eligible. Listing depends on whether the patent claims the approved drug product or an approved method of use and satisfies FDA listing requirements.

Does Vicoprofen have biosimilar competition?

No. Vicoprofen is a small-molecule drug, not a biologic. Competition comes from generic hydrocodone/ibuprofen products, not biosimilars.

What is the highest-value excipient innovation for Vicoprofen?

A low-segregation, directly compressible excipient system that improves hydrocodone content uniformity, tablet robustness, dissolution, and manufacturing yield offers the most practical balance of regulatory feasibility and commercial value.

References

1. U.S. Food and Drug Administration. (1997). Vicoprofen (hydrocodone bitartrate and ibuprofen) prescribing information, NDA 20-716.

2. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Orange Book.

4. U.S. Drug Enforcement Administration. (2024). Controlled substances and regulated pharmaceutical manufacturing requirements.

5. U.S. Food and Drug Administration. (2024). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.